INSILICO - VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND TENACIA BIOTECHNOLOGY EXPAND AI-DRIVEN CNS COLLABORATION WITH ADDITIONAL DEAL VALUE UP TO USD94.75 MILLION

INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 (Incorporated in the Cayman Islands with limited liability) (Stock code: 3696) VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND TENACIA BIOTECHNOLOGY EXPAND AI-DRIVEN CNS COLLABORATION WITH ADDITIONAL DEAL VALUE UP TO USD94.75 MILLION This announcement is made by InSilico Medicine Cayman TopCo (the "Company", together with its subsidiaries, the "Group" or "Insilico Medicine") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the "Board") is pleased to announce that, building on the productive collaboration over the past year, Insilico Medicine and Tenacia Biotechnology (Hong kong) Co., Limited ("Tenacia Biotechnology"), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, have entered into an expanded AI-driven R&D collaboration (the "Collaboration"). Through the Collaboration, the two parties aim to provide a broader and more precise set of therapeutic options for highly challenging nerve system-related conditions, contributing to the mitigation of late-stage development risk and improvement of potential clinical benefit. Under the terms of the relevant agreement, the parties will leverage generative AI to jointly develop an additional innovative molecule candidate with defined properties for challenging neurological diseases and advance it to the preclinical candidate (PCC) stage to address differentiated clinical needs. The expanded collaboration carries additional potential deal value of up to USD94.75 million, with Insilico Medicine being eligible to receive near-term and milestone payments from Tenacia Biotechnology. About Insilico Medicine Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com. Forward Looking Statement There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors. By order of the Board InSilico Medicine Cayman TopCo Mr. Aleksandrs Zavoronkovs, Ph.D. Chairman, Executive Director, CEO and CBO Hong Kong, March 26, 2026